Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trialJingjing Li, Jieer Ying, Da Li et al.|Nature Communications|2025Cited by 12
A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.Jing‐Jing Li, Jieer Ying, Qi Xu et al.|Journal of Clinical Oncology|2022Cited by 7
Phase Ⅱ Study of Combined Sintilimab and Anlotinib with Gemcitabine plus Cisplatin in Advanced Biliary Tract Cancer: Efficacy, Safety and Optimize DoseJingjing Li, Jieer Ying, Shurui Zhou et al.|Research Square|2024Cited by 1